Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
BioNeurix Receives Warning Letter from FDA
December 26, 2012
1 Min Read
WASHINGTON Earlier this year, FDA warned BioNeurix Corp. that it is making unlawful claims on its website, www.pharma-tree.com.
In the Oct. 15 letter, the agency declared that its products "Blood Sugar 360", "Amoryn", "Seredyn" and "Mellodyn" are promoted for conditions that cause them to be drugs because they are intended to cure, mitigate, treat or prevent a disease. The agency cited several claims referencing diabetes.
The marketing claims violate the Federal Food, Drug, and Cosmetic Act, FDA alleged.
BioNeurix was given the customary 15 days to respond to FDA's warning letter.
You May Also Like